Ixazomib Citrate

Summary

Ixazomib Citrate (CHEMBL3545432) is an approved small-molecule prodrug; indicated across 15 conditions including plasma cell myeloma and lymphoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 15 conditions
• Clinical trials: 47
• Chemistry: 517.1 Da · C20H23BCl2N2O9

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3545432
Name	Ixazomib Citrate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	56844015
ChEBI	CHEBI:90939
Molecular formula	C20H23BCl2N2O9
Molecular weight	517.1
InChIKey	MBOMYENWWXQSNW-AWEZNQCLSA-N

SMILES: B1(OC(=O)C(O1)(CC(=O)O)CC(=O)O)[C@H](CC(C)C)NC(=O)CNC(=O)C2=C(C=CC(=C2)Cl)Cl

IUPAC name: 2-[4-(carboxymethyl)-2-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-5-oxo-1,3,2-dioxaborolan-4-yl]acetic acid

ChEBI definition: A glycine derivative that is the amide obtained by formal condensation of the carboxy group of N-(2,5-dichlorobenzoyl)glycine with the amino group of 2,2’-{2-[(1R)-1-amino-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diyl}diacetic acid. A prodrug for ixazomib that is used in combination therapy for treatment of multiple myeloma.

Pharmacological roles (ChEBI): prodrug, proteasome inhibitor, orphan drug, antineoplastic agent, apoptosis inducer.

Also known as: Ixazomib citrate, MLN-9708, MLN9708, Ninlaro, IXAZOMIB CITRATE

Patent coverage: 1,061 distinct patent families (2,453 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 2,344 (96%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Proteasome Macropain subunit MB1.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PSMB5	9.03	Ki	0.93	nM	CHEMBL_ACT_26133923
PSMB5	8.47	IC50	3.4	nM	CHEMBL_ACT_26133924

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

15 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
plasma cell myeloma	4	MONDO:0009693	EFO:0001378
lymphoma	2	MONDO:0005062	EFO:0000574
plasma cell leukemia	2	MONDO:0018689	EFO:0006475
plasmacytoma	2	MONDO:0005615	EFO:0006738
Waldenstrom macroglobulinemia	2	MONDO:0100280	EFO:0009441
mantle cell lymphoma	2	MONDO:0018876	EFO:1001469
Kaposi’s sarcoma	2	MONDO:0005055	EFO:0000558
acute myeloid leukemia	1	MONDO:0018874	EFO:0000222
acute lymphoblastic leukemia	1	MONDO:0004967	EFO:0000220
breast neoplasm	1	MONDO:0021100	MONDO:0007254
hereditary amyloidosis	1	MONDO:0018634	MONDO:0019438
neoplasm	1	MONDO:0005070	MONDO:0004992
glioblastoma	0	MONDO:0018177	EFO:0000519

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 47.

Phase distribution

Phase	Trials
PHASE2	23
PHASE1/PHASE2	10
PHASE1	10
PHASE3	3
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02181413	PHASE3	COMPLETED	A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant
NCT02406144	PHASE3	COMPLETED	Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple Myeloma
NCT03941860	PHASE3	COMPLETED	Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial
NCT02339922	PHASE2	ACTIVE_NOT_RECRUITING	Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
NCT02420847	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery
NCT02542657	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma
NCT03587662	PHASE2	ACTIVE_NOT_RECRUITING	Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
NCT04305691	PHASE2	RECRUITING	Trial of Ixazomib for Kaposi Sarcoma
NCT01415882	PHASE2	COMPLETED	Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib
NCT01660997	PHASE2	WITHDRAWN	MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma
NCT01718743	PHASE2	COMPLETED	Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT01864018	PHASE1/PHASE2	COMPLETED	Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis
NCT01936532	PHASE2	COMPLETED	Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)
NCT02057640	PHASE1/PHASE2	COMPLETED	MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma
NCT02119468	PHASE1/PHASE2	COMPLETED	Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
NCT02158975	PHASE2	COMPLETED	Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas
NCT02168101	PHASE2	COMPLETED	Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma
NCT02169791	PHASE2	COMPLETED	Nonmyeloablative Haploidentical Transplant Followed by MLN9708
NCT02250300	PHASE1/PHASE2	COMPLETED	MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic Transplantation
NCT02389517	PHASE2	COMPLETED	Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant
NCT02477215	PHASE1/PHASE2	COMPLETED	Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT02481310	PHASE1/PHASE2	UNKNOWN	Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
NCT02513498	PHASE2	COMPLETED	Ixazomib Citrate in Treating Patients With Chronic Graft-versus-Host Disease
NCT02547662	PHASE2	COMPLETED	Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia
NCT02586038	PHASE2	COMPLETED	STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS
NCT02619682	PHASE2	COMPLETED	Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma
NCT02633059	PHASE1/PHASE2	COMPLETED	Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
NCT03012880	PHASE2	COMPLETED	Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT03202628	PHASE2	COMPLETED	Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma
NCT03457142	PHASE2	TERMINATED	Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy
NCT03506360	PHASE2	COMPLETED	Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
NCT03506373	PHASE2	TERMINATED	Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia
NCT03731832	PHASE2	COMPLETED	Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma
NCT03856112	PHASE1/PHASE2	WITHDRAWN	Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma
NCT03965624	PHASE2	WITHDRAWN	Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopenia
NCT04047797	PHASE2	TERMINATED	Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT04847453	PHASE1	ACTIVE_NOT_RECRUITING	Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis
NCT00963820	PHASE1	COMPLETED	Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma
NCT01887587	PHASE1	TERMINATED	Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia
NCT02042989	PHASE1	COMPLETED	MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).